Duke at

Virtual American Society of Clinical Oncology 2020
Beginning Friday, May 29 at 8:00 AM ET

- Oral, Poster Discussion, and Poster Sessions, as well as track-based Clinical Science Symposia, will be available on demand.
- Registrants will have exclusive access to hundreds of video and slide presentations, as well as discussant commentary for 180 days.

Saturday, May 30

- **9:30 AM ET**: Opening Session with President's Address from Howard A. “Skip” Burris III, MD and Guest Speaker's Address by David Fajgenbaum, MD
- **10:30 AM ET**: Highlights Sessions: Breast Cancer; Head and Neck Cancer
- **11:00 AM ET**: Highlights Sessions: Gastrointestinal Cancers; Central Nervous System Tumors
- **11:30 AM ET**: Highlights Sessions: Hematological Malignancies; Gynecological Cancers
- **1:00 PM ET**: Special Clinical Science Symposium: Harnessing Immunotherapy with Novel Approaches Beyond Checkpoint Inhibitors
- **2:30 PM ET**: Highlights Sessions: Cancer Prevention, Risk Reduction, and Genetics; Symptoms and Survivorship
- **3:30 PM ET**: Special Clinical Science Symposium: Redefining Cancer of Unknown Primary: Is Genomics the Answer?
- **4:30 PM ET**: Special Clinical Science Symposium: Cancer Care in the time of COVID: Assessing Impact and Future Directions

Sunday, May 31

- **9:30 AM ET**: Highlights Sessions: Melanoma; Health Services Research and Quality Improvement
- **10:00 AM ET**: Highlights Sessions: Lung Cancer; Pediatric Oncology
- **10:30 AM ET**: Special Clinical Science Symposium: Drug Development for Rare Mutations: The Opportunity to Unite and Conquer
- **1:00 PM ET**: Plenary Session
- **3:30 PM ET**: Highlights Sessions: Genitourinary Cancers; Sarcoma
- **4:00 PM ET**: Highlights Sessions: Developmental Therapeutics; Care Delivery and Regulatory Policy
ASCO Participation Provided by our Duke Colleagues:

Tian Zhang, MD
- A Featured Voice for #ASCO20 on Twitter
- Discussant for the Genitourinary Cancer—Kidney and Bladder poster discussion session; “Single agent targeted agents vs combinations with IO: what is the optimal future therapy in advanced urothelial cancer?”

Vishal Vashistha, MD
Abstract Title: Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA National Precision Oncology Program.
Session Title: Care Delivery and Regulatory Policy
Session Type: Oral Abstract Session / Presenter
Date: Friday, May 29, 2020
Time: 8:00 AM - 11:00 AM
Abstract Discussant: Devika Govind Das, MBBS

Brent Hanks, MD, PhD
Discussant - Clinical Science Symposium
“Systems Biology Approaches to Immunotherapy Response and Toxicity”
Presentation entitled ‘Rise of the Machines: AI in Predicting Immunotherapy Outcomes’.

Landon Brown, MD
- Oral Presentation of abstract at ASCO 2020 under Dr. Andrew Armstrong’s mentorship; https://meetinglibrary.asco.org/record/186713/abstract
- Recipient - Conquer Cancer ASCO Merit Award for this abstract: “Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types”; Abstract #: 3007

April Salama, MD
Poster Discussant for melanoma/skin cancers- “Characterizing Long Term Outcomes in Metastatic Melanoma in 2020”

Scientific Program Committee

Breast Cancer – Local/Regional/Adjuvant
Eun Sil (Shelby) Hwang, MD

Melanoma/Skin Cancers
April Salama, MD
Perceptions of process barriers to lung cancer screening at community oncology programs.

SESSION
Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)
Linda Sutton, Lisi Lotz, Eileen Hom V Hom, Trudy Pendergraft

ABSTRACT e19218

Stem cell transplant and financial toxicity: A single-center prospective cohort analysis.

SESSION
Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)
Syed Huseinini, Yi Ren, Meagan Lew, Lauren Bohannon, Jillian C Thompson, Yousuf Zafar, Anthony Derek Sung

ABSTRACT e19373

Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.

SESSION
Publication Only: Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

ABSTRACT e17090

Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).

SESSION
Publication Only: Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)
Jeffrey Melson Clarke, Xiaofei F. Wang, Lin Gu, Marvaretta Miesha Stevenson, Tom Stinchcombe, Sundhar Ramalingam, Scott Joseph Antonia, Afreen Shariar, Jennifer Garst, Jeffrey Crawford, Neal E. Ready

ABSTRACT e21683

A precision medicine drug discovery pipeline to identify dual CDK2/9 inhibition as a novel treatment for colorectal cancer.

SESSION
Publication Only: Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S)
Roham Salman Roghani, Ali Sanjari moghaddam, Gabrielle Rupprecht, Erdem Altunel, So Young Kim, Shannon McCall, Beatrice Thomas, Katie Ware, Jason Somarelli, David S. Hsu

ABSTRACT e16056

Missing data in breast cancer: Relationship with survival in national databases.

SESSION
Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)
Jennifer Kay Plichta, Christel N. Rushing, Holly C. Lewis, Dan G. Blazer, Terry Hystop, Rachel Adams Greenup

ABSTRACT e19114

Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL).

SESSION
Publication Only: Symptoms and Survivorship

AUTHOR(S)
Danielle M. Brander, Kevin C. Oeffinger, Melissa A. Greiner, Michaela Ann Dinan

ABSTRACT e24050

Fatigue trajectories in long-term non-Hodgkin lymphoma survivors.

SESSION
Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

AUTHOR(S)
Matthew Roger LeBlanc, Sheryl Zimmerman, Mariam Kayle, Thomas William LeBlanc, Kathryn Elizabeth Hudson, Sophia Kustas Smith

ABSTRACT e20053

Patterns of inpatient palliative care consultation for patients with brain and spine metastases.

SESSION
Publication Only: Symptoms and Survivorship

AUTHOR(S)
Elizabeth Howell, Meghan Price, Tara Dalton, Theresa Williamson, Arif Kamal, Rory Goodwin

ABSTRACT e24117

Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs).

SESSION
Publication Only: Breast Cancer—Metastatic

AUTHOR(S)
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: Are some patients missing out?

**SESSION**
Publication Only: Gynecologic Cancer

**AUTHOR(S)**
Haley Moss, Angeles Alvarez Secord, Jessica Perhanidis, Carol Hawkes

**ABSTRACT**
e13096

An analysis of trends in prostate cancer treatment from a CMS database.

**SESSION**
Publication Only: Health Services Research and Quality Improvement

**AUTHOR(S)**
Andre A. Konski, Elizabeth Lin Jewell, Laura J Havrilesky, Jason A. Efstathiou, Peter A. Johnstone

**ABSTRACT**
e19288

A prospective cohort study of stability in preference for place of death among patients with stage IV cancer.

**SESSION**
Publication Only: Symptoms and Survivorship

**AUTHOR(S)**
Ling En Koh, Chetna Malhotra, Eric Finkelstein, COMPASS Study Group

**ABSTRACT**
e24148

Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.

**SESSION**
Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**AUTHOR(S)**

**ABSTRACT**
e20004

Optimizing cancer care using digital technologies requires coordinated multi-stakeholder effort.

**SESSION**
Publication Only: Care Delivery and Regulatory Policy

**AUTHOR(S)**
Sendhilnathan Ramalingam, A Jay Holmgren, Jennifer Goldsack, Adam Conner-Simons, Edmondo Robinson

**ABSTRACT**
e14108

Can a brief multimedia intervention facilitate breast cancer patients’ communication about sexual health? Findings from a randomized controlled trial.

**SESSION**
Publication Only: Symptoms and Survivorship

**AUTHOR(S)**
Jennifer B. Reese, Mary Catherine Beach, Kristen A. Sorice, Whitney Pollard, Mary Beryl Daly, Elizabeth A. Handorf, Laura S Porter, James A. Tulsky, Stephen J Lepore

**ABSTRACT**
e24179


**SESSION**
Publication Only: Cancer Prevention, Risk Reduction, and Genetics

**AUTHOR(S)**
Gillian Hooker, Dawn C. Allain, Adam H Buchanan, Melanie Care, Laura Conway, Alessandra Cumming, Shannan Dixon, Kristin Paulison-Núñez, Sara Riordan, Janet Williams

**ABSTRACT**
e13526

Brain metastasis from esophageal squamous cell carcinoma: Clinical characteristics and prognosis.

**SESSION**
Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**AUTHOR(S)**
Linlin Xiao, Yvonne Marie Mowery, Jun Wang, Min Zhao, Shaowu Jing, Guangbin Gao

**ABSTRACT**
e16525

Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer.

**SESSION**
Publication Only: Health Services Research and Quality Improvement

**AUTHOR(S)**
Robert S. Epstein, Matti S. Aapro, Upal K. Basu Ray, Tehseen Salimi, JoAnn Krenitsky, Megan L. Leone-Perkins, Jeffrey Crawford

**ABSTRACT**
e19299

Interferon gamma resistance in setting of LKB1 loss: Phenotypic characterization and investigation of mechanism.

**SESSION**
Real-world incidence and management of durable complete response in de novo metastatic HER2-positive breast cancer.

**SESSION**
Publication Only: Breast Cancer—Metastatic

**AUTHOR(S)**
Claire Elizabeth Powers Smith, Paul Kelly Marcom, Zahi Ibrahim Mitri

Long-term outcomes among BCG-treated high-risk non-muscle invasive bladder cancer patients in an equal access setting.

**SESSION**
Publication Only: Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**
Stephen B. Williams, Lauren Howard, Meagan Foster, Zachary William Abraham Klaassen, Jan Sieluk, Haojie Li, Kentaro Imai, Eric Sbar, Amanda M. De Hoedt, Stephen J. Freedland

Real-world examination of remission patterns in patients (pts) with acute myeloid leukemia (AML).

**SESSION**
Publication Only: Health Services Research and Quality Improvement

**AUTHOR(S)**
Ashley Tabah, David Huggar, Brenna L. Brady, Krutika Jariwala-Parikh, Ronda Copher, Thomas William LeBlanc

Adult lymphoma-associated hemophagocytic lymphohistiocytosis: A clinical case series in a predominantly Hispanic cohort from the University of Miami/Jackson Memorial Hospital.

**SESSION**
Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**AUTHOR(S)**
Eduardo Edelman Saul, Amrita Desai, Jennifer Chapman, Lazaros J. Lekakis, Alexandra Stefanovic, Agustin Pimentel

Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies.

**SESSION**
Publication Only: Melanoma/Skin Cancers

**AUTHOR(S)**
Jinho Lee, Marilyne Labrie, Gen Yong, Todd Camp, Hongli Ma, Megan Grout, Wei Xu, Georgia Beasley, Lynn Mara Schuchter, Suzanne McGgettigan, Donald M. O'Rourke, Meenhard Herlyn, Christopher L. Corless, Gordon B. Mills, Gao Zhang

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).

**SESSION**
Publication Only: Lung Cancer—Non-Small Cell Metastatic

**AUTHOR(S)**
Suresh S. Ramalingam, Tom Stinchcombe, Gregory James Gershtner, Missak Haigentz, Surya Vangala, Megan Parsi, John W. Heybum, Victor Kabala, Tuhina Prasad, Andres A. Gutierrez, Jonathan Wade Goldman, ADXS-503 Author's Group

Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).

**SESSION**
Publication Only: Cancer Prevention, Risk Reduction, and Genetics

**AUTHOR(S)**
Daniel Louis Hertz, Nicholas Bradley Larson, Timothy Pierpont, Nancy L. Bartlett, Andrew David Zelenetz, Wyndham Hopkins Wilson, John Paul Leonard, Sin-Ho Jung, Shaun M. Riska, Kristy L. Richards

Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.

**SESSION**
Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**
Jasmine Jiemei Wang, Pai-Chi Teng, Yu Jen Jan, Jie-Fu Chen, Galen Cook-Wiens, Nu Yao, Gina Chia-Yi Chu, Pin-Jung Chen, Hao Ho, Yi-Tee Lee, Jiaotl Huang, Ker-Chau Li, Leland WK Chung, Yazhen Zhu, Michael Freeman, Andre Rogatko, Ju Dong Yang, Hsian-Rong Tseng, Edwin Melencio Posadas

Genomic biomarkers to determine survival in Multicenter Study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment.
Enrollment barriers of adolescents and young adults (AYA) on the non-chemotherapy arm of ARST1321.

Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.

Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.

The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).
Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance).

SESSION: Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S): Francesca Battaglin, Fang-Shu Ou, Xueping Qu, Monica M. Bertagnolli, Howard S. Hochster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Tyler J. Zemla, Charles David Blanke, Alan P. Venook, Omar Kabbarah, Heinz-Josef Lenz, Federico Innocenti

ABSTRACT / POSTER: 4086 • 78

Characterization of sociodemographic and clinicopathological features and associated outcomes of patients (Pts) with anal squamous cell cancer (ASCC): Analysis of 44,084 pts in the National Cancer Database (NCDB).

SESSION: Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S): Joanna Alyse Young, Sally Jeanne Trufan, William Mills Wornlow, Laura W. Musselwhite, Reza Nazemzadeh, Kunal C. Kollia, Seungjean Chai, John Stuart Salmon, Jimmy J. Hwang, Edward S. Kim, Derek Raghavan, Mohamed E. Salem

ABSTRACT / POSTER: 4052 • 44

Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomized controlled trials.

SESSION: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

AUTHOR(S): Ulrich Ronellenfitsch, Katrin Jensen, Svenja Seide, Meinhard Kieser, Matthias Schwarzbach, Tracy E Sanger, Bryan Burmeister, David Paul Kelsen, Donna Niedzwiecki, Guillaume Piessens, Christoph Schumacher, Susan Urba, Cornelis J. H. Van De Velde, Marc Ychou, Ralf Dieter Hofheinz, Sylvie Lorenzen

ABSTRACT / POSTER: 4533 • 141

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

SESSION: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary


ABSTRACT / POSTER: 4003

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

SESSION: Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S): Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler J. Zemla, Priya Kumthekar, Katherine A Guthrie, Felix Couture, J. Phillip Kuebler, Johanna C. Bendell, Pankaj Kumar, DeQuincy Andrew Lewis, Benjamin R. Tan, Monica M. Bertagnolli, Axel Grothey, Howard S. Hochster, Richard M. Goldberg, Alan P. Venook, Charles David Blanke, Anthony Frank Shields

ABSTRACT: 4018 • 10

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS\textsuperscript{G12C}, in patients with advanced colorectal cancer.

SESSION: Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S): Marwan Fakih, Jayesh Desai, Yasutoshi Kubok, John H. Strickler, Timothy Jay Price, Greg Andrew Dum, Gerald Steven Falchook, Crystal S. Denlinger, John C. Krauss, Geoffrey Shapiro, Tae Won Kim, Keunchil Park, Andrew L. Coveler, Pamela N. Munder, Bob T. Li, June Kim, Haby Adel Haney, Gattea Ngamchamnanirth, David S. Hong

ABSTRACT / POSTER: 4015 • 7

Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

SESSION: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

AUTHOR(S): Chiara Cremolini, Carlotta Antoniotti, Alexander Stein, Johanna C. Bendell, Thomas Gruenberger, Gianluca Masi, Elena Ongaro, Herbert Hurwitz, Alfredo Falcone, Hans-Joachim Schmoll, Massimo Di Maio
Sarcoma

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).

SESSION
Sarcoma

AUTHOR(S)
Matthew Ingham, Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark Andrew Dickson, Richard F. Riedel, Steven Attia, Anthony D. Elias, David A. Liebner, Mark Agulnik, Katherine Anne Thomton, Varun Monga, Brian Andrew Van Tine, Gary K. Schwartz, William D. Tap

ABSTRACT / POSTER 11562 ● 450

Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.

SESSION
Sarcoma

AUTHOR(S)
Andrew J. Wagner, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian Andrew Van Tine, Rashmi Chugh, Lee D. Cranmer, Erlinda Maria Gordon, Jason L. Homick, David J. Kwiatkowski, Heng Du, Berta Grigorian, Anita N. Schmid, Shihe Hou, Katherine Harris, Neil Desai, Mark Andrew Dickson

ABSTRACT / POSTER 11516 ● 404
Patient preferences and expectations of systemic therapy in renal cell carcinoma.

**SESSION**
Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**
Dena Battle, Cristiane Decat Bergerot, Pavlos Msaouel, Eric Jonasch, Tian Zhang, Daniel J. George, Michael D. Staehler

**ABSTRACT / POSTER** 5083 • 152

Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.

**SESSION**
Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**
Dena Battle, Cristiane Decat Bergerot, Pavlos Msaouel, Tian Zhang, Daniel J. George, Michael D. Staehler

**ABSTRACT / POSTER** 5084 • 153

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

**SESSION**
Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**

**ABSTRACT / POSTER** TPS5100 • 169

A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**
Emerson A. Lim, Todd Michael Bauer, Manish R. Patel, Gerald Steven Falchuk, Janet L. Karlix, Jennifer Hsing Choe, Daniel J. George, Ganesh M. Mugundu, Elizabeth Pilling, Hufang Chen, Bolan Linghu, Lara McGrath, Wentlin Shao, Melinda S. Merchant, Ben Sidders, Kris F. Sachsenmeier, Gayle Pageau Pouliot, Charles G. Drake, Johanna C. Bendell

**ABSTRACT / POSTER** 5518 • 99

Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer.

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** 5563 • 144

Comparative effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: A parametric survival network meta-analysis of randomized controlled trials.

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**
Lin Wang, Channing Judith Paller, Hwanhee Hong, Anthony De Felice, Caleb Alexander, Otis W. Brawley

**ABSTRACT / POSTER** 5532 • 113

DAROL: DARolutamide Observational study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**
Evan Y. Yu, Christopher Michael Pieczonka, Alberto Briganti, Declan G. Murphy, Thierry Lebret, Murilo Luz, Hiroyoshi Suzuki, Antoine Thiery-Vuillemin, Jorge A. Ortiz, Rongjin Guan, Andrew J. Armstrong

**ABSTRACT / POSTER** TPS5593 • 174

DarolACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC).

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**
Tomasz M. Beer, Neal D. Shore, Alicia K. Morgans, Kerri M. Winters-Stone, Jeffrey Scott Wefel, Jorge A. Ortiz, John A. Reeves, Daniel J. George

**ABSTRACT / POSTER** TPS5587 • 168


**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

**SESSION** Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**
Jonathan E. Rosenberg, Thomas W. Flaig, Terence W. Friedlander, Matthew I. Milowsky, Sandy Srinivas, Daniel Peter Petrylak, Jaime R. Merchant, Mehmet Asim Bilen, Anne-Sophie Carret, Nancy Yuan, Carolyn Sasse, Christopher J. Holmes

**ABSTRACT / POSTER** 5044 • 113

Phase II neoadjuvant (N)-gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.

**SESSION** Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**

**ABSTRACT / POSTER** 5019 • 88

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

**SESSION** Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**

**ABSTRACT / POSTER** TPS5101 • 170

HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.

**SESSION** Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT** 5602

Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.

**SESSION** Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**
Neal D. Shore, Andrew J. Armstrong, Russell Zeig Szmulewitz, Daniel Peter Petrylak, Jeffrey Holzbeierlein, Amauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P. Haas, Amulf Stenzl

**ABSTRACT / POSTER** 5547 • 128

Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

**SESSION** Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** 5567 • 148

Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

**SESSION** Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** TPS5589 • 170

Phase Ib/II neoadjuvant (N)-pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)-eligible cohort of HCRN GU14-188.

**SESSION** Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**
**Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.**

**SESSION**
Genitourinary Cancer—Kidney and Bladder

**AUTHOR(S)**
Nataliya Mar, Terence W. Friedlander, Christopher J. Holmes, Thomas W. Flaig, Mehmet Asim Bilen, Arjun Vasant Balar, Elizabeth Henry, Sandy Srivivas, Jonathan E. Rosenberg, Daniel Peter Petrylak, Earle Frederick Burgess, Jaime R. Menchan, Scott T. Tagawa, Anne-Sophie Carmel, Joyce Leta Steinberg, Marya F. Chaney, Matthew I. Milowsky

**ABSTRACT / POSTER** TPS5092 • 161

**Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.**

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** 5565 • 146

**Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.**

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** 5568 • 149

**KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).**

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** 5543 • 124

**Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.**

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** 5584 • 165

**Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.**

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** 5544 • 125

**Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.**

**SESSION**
Genitourinary Cancer—Prostate, Testicular, and Penile

**AUTHOR(S)**

**ABSTRACT / POSTER** 5550 • 131
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

SESSION
Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)
Henry Jacob Conter, Neal D. Shore, William R. Berry, Peter C.C. Fong, Jose Maria M. Piulats Rodriguez, Leonard Joseph Appleman, Tilman Todenhöfer, Gwenaelle Gravis, Brigitte Laguerre, Howard Gurney, Margitta Retz, Emanuela Romano, Loic Mourey, Johann S. De Bono, Audrey E. Kam, Urban Emmenegger, Haiyan Wu, Ping Qiu, Charles Schloss, Evan Y. Yu

ABSTRACT / POSTER 5545 • 126
Lung SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

SESSION Lung Cancer—Non-Small Cell Metastatic


ABSTRACT / POSTER 9623 • 389

AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).

SESSION Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

AUTHOR(S) Helen J. Ross, David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, Katja Schulze, JaneMichelle Michelle Brockman, Xiaofei F. Wang, Junheng Gao, Everett E. Vokes, Tom Stinchcombe

ABSTRACT / POSTER 9045 • 238

Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).

SESSION Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S) Joao Victor Machado Alessi, Carolyn Glass, Biagio Ricciuti, Liam F. Spurr, Lynette M. Sholl, Mark M. Awad

ABSTRACT / POSTER 9577 • 343

NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer.

SESSION Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers


ABSTRACT / POSTER TPS9082 • 275

Pezotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

SESSION Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S) Xiuning Le, Jonathan Wade Goldman, Jeffrey Nelson Clarke, Nishan Tchekmedyian, Zofia Piotrowska, David Chu, Gajanan Bhat, Francois M. Lebel, Mark A. Socinski

ABSTRACT / POSTER 9514 • 280

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).

SESSION Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S) Andreas Nicholas Saltos, Tawee Tanvetyanon, Ben C. Creelan, Michael Rahman Shafique, Scott Joseph Antonia, Eric B. Haura, Hong Zheng, Margaret Barlow, James Saller, Anna Castellano-Fomelli, Antoine Richards, Ram Thapa, Theresa A. Boyle, Dung-Tsa Chen, Amer A Beg, Jhanelle Elaine Gray

ABSTRACT / POSTER 9567 • 333


SESSION Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers


ABSTRACT / POSTER 9065 • 258

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

SESSION Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

AUTHOR(S) Jacob Sands, Sumithra J. Mandrek, Geoffrey R. Oxnard, David E. Kozono, Shauna L Hillman, Suzanne Eleanor Dahlberg, Zhuxin Sun, Jamie E. Chaft, Ramaswamy Govindan, David E. Gerber, Jhanelle Elaine Gray, Shahin M. Malik, Margaret M. Mooney, Pas A. Janne, Everett E. Vokes, Karen Kelly, Suresh S. Ramalingam, Tom Stinchcombe

ABSTRACT / POSTER TPS9077 • 270
Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

SESSION
Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)
Justin F. Gainor, Jeffrey Gary Schneider, Martin Gutierrez, James Michael Orcutt, Gene Grant Finley, Gregory Alan Otterson, Igor I. Ryblin, Pavan S. Reddy, Leora Horn, Julie R. Brahmer, Bruno R. Bastos, Mark M. Awad, Matthew David Hellmann, Suresh S. Ramalingam, Neal E. Ready, David R. Spigel, Ravi S. Kasisnathan, Cécile Dorange, Hossein Borghaei

ABSTRACT / POSTER 9560 • 326
Breast
Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery.

SESSION
Breast Cancer—Local/Regional/Adjuvant

AUTHOR(S)
Marc D. Ryser, Laura Hendrix, Samantha M. Thomas, Thomas Lynch, Anne McCarthy, Zahed Mohammed, Amanda B. Francescati, Elizabeth S. Frank, Ann H. Partridge, Alastair Mark Thompson, Terry Hyslop, Eun-Sil Shelley Hwang

ABSTRACT / POSTER 519 • 11

Identification of pathogenic \( ROS1 \) alterations in cell-free DNA (cfDNA) from patients with breast cancer.

SESSION
Breast Cancer—Metastatic

AUTHOR(S)
Jeremy Meyer Force, Mary Love Taylor, Lelah Dusbosky, Jennifer Yen, Paul Kelly Marcom, Carey K. Anders, Jeffrey R Marks

ABSTRACT / POSTER 1031 • 116

Disparities in receipt of and time to adjuvant therapy after lumpectomy.

SESSION
Breast Cancer—Local/Regional/Adjuvant

AUTHOR(S)
Irene Dankwa-Mullan, M. Christopher Roebuck, Joseph Tkacz, Oluwadamilola Motunrayo Fayanju, Yi Ren, Gretchen Purcell Jackson, Yull Edwin Arriaga

ABSTRACT / POSTER 534 • 26

Understanding and predicting fatigue, cardiovascular (CV) decline & events after breast cancer treatment (UPBEAT): A prospective multi-center wake forest NCORP research-base study.

SESSION
Breast Cancer—Local/Regional/Adjuvant

AUTHOR(S)

ABSTRACT / POSTER TPS602 • 94

Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).

SESSION
Breast Cancer—Metastatic

AUTHOR(S)

ABSTRACT / POSTER 1055 • 140


SESSION
Breast Cancer—Metastatic

AUTHOR(S)

ABSTRACT / POSTER TPS1102 • 187

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

SESSION
Breast Cancer—Metastatic

AUTHOR(S)
Patricia LoRusso, Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisin M. Connolly, Erin Elizabeth Roesch, Anosheh Afghahi, Hyo S. Han, Rita Nanda, Gerburg M. Wulf, Hadeel Assad, Haeseong Park, Elizabeth Claire Dees, Jeremy Meyer Force, Anne M. Noonan, Adam Brufsky, Vandana G Abramson, Barbara B. Haley, Saundra S. Buys, Elad Sharon, Kurt A. Schalper

ABSTRACT / POSTER TPS1105 • 162

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).

SESSION
Breast Cancer—Metastatic

AUTHOR(S)

ABSTRACT 1005
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

SESSION
Breast Cancer—Metastatic

AUTHOR(S)

ABSTRACT 1001

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

SESSION
Breast Cancer—Metastatic

AUTHOR(S)

ABSTRACT 1002
**Central Nervous System**

**BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.**

**SESSION** Central Nervous System Tumors

**AUTHOR(S)**

Katherine B. Peters, Adam Louis Cohen, Nicholas A. Butowsky, John L. Villano, Pierre Giglio, Tresa McGranahan, Chi Zhang, Timothy Francis Cloughesyy, James Emmett Hemdon, Patrick Healy, David MacLeod, Sara Penchev, David Silberstein, Ines Batinic-Haberle, Ivan Spasojevic, Shayne Gad, David Radoff, Daniel Barboriak, James Crapo

**ABSTRACT / POSTER** TPS2577 • 68

Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).

**SESSION** Central Nervous System Tumors

**AUTHOR(S)**

Annick Desjardins, Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret O Johnson, Stevie Threatt, Chevelle A Bullock, James Emmett Hemdon, Patrick Healy, Eric S Lipp, John H. Sampson, Allan H. Friedman, Henry S. Friedman, David M. Ashley, Darell D. Bigner

**ABSTRACT / POSTER** TPS2566 • 57

Alliance A071701: Genomically guided treatment trial in brain metastases.

**SESSION** Central Nervous System Tumors

**AUTHOR(S)**


**ABSTRACT / POSTER** TPS2573 • 64

Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.

**SESSION** Central Nervous System Tumors

**AUTHOR(S)**

Ingo K. Mellinghoff, Katherine B. Peters, Timothy Francis Cloughesyy, Howard A. Burris III, Elizabeth Anne Maher, Filip Janku, Gregory Michael Cote, Macarena Ines De La Fuente, Jennifer Leigh Clarke, Kha Le, Li Liu, Man Yuen, Marissa Amofsky, Islam Hass an, Lori Steelman, Shuchi Suman Pandya, Patrick Y. Wen

**ABSTRACT** 2504

INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

**SESSION** Central Nervous System Tumors

**AUTHOR(S)**

Ingo K. Mellinghoff, Martin J. Van Den Bent, Jennifer Leigh Clarke, Elizabeth Anne Maher, Katherine B. Peters, Mehdi Touat, John Frederick De Groot, Macarena Ines De La Fuente, Isabel Antillaga-romany, Wolfgang Wick, Benjamin M. Ellingson, Steven Schoenfeld, Feng Tai, Kha Le, Min Lu, Lori Steelman, Islam Hassan, Shuchi Suman Pandya, Patrick Y. Wen, Timothy Francis Cloughesyy

**ABSTRACT / POSTER** TPS2574 • 65

Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).

**SESSION** Central Nervous System Tumors

**AUTHOR(S)**


**ABSTRACT** 2501

MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.

**SESSION** Central Nervous System Tumors

**AUTHOR(S)**

John H. Sampson, Achal Achrol, Manish K. Aghi, Krystof Bankiewicz, Martin Bexon, Steven Brem, Andrew Jacob Brenner, Chandip Chandhasin, Sajeel A. Chowdhary, Melissa Coello, Sunit Das, Seunggu Jude Han, Santosh Kesari, Fahar Merchant, Nina Merchant, Dina Randazzo, Michael A. Vogelbaum, Frank Vrionis, Miroslaw Zabek, Nicholas A. Butowsky

**ABSTRACT / POSTER** TPS2513 • 4

Molecular features of gliomas with high tumor mutational burden.

**SESSION** Central Nervous System Tumors
Hem Malignancies


**SESSION**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

**AUTHOR(S)**

**ABSTRACT / POSTER**
TPS7563 • 336

A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.

**SESSION**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

**AUTHOR(S)**

**ABSTRACT / POSTER**
TPS7564 • 337

A fork in the road: A mixed methods study exploring why older adults with acute myeloid leukemia choose different treatment paths.

**SESSION**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

**AUTHOR(S)**

**ABSTRACT / POSTER**
7520 • 293


**SESSION**
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**AUTHOR(S)**
Kai Fu, Guohua Yu, Chengfeng Bi, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad, Brian K. Link, Craig R. Nichols, Paul M. Barr, Brad S. Kahl, Douglas Stewart, Stefan K Barta, Anne Beaver, Ranjana H. Advani, Peter Martin, Timothy Greiner, Dennis Weisenburger, James O. Armitage, Julie Vose

**ABSTRACT / POSTER**
8035 • 368

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

**SESSION**
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**AUTHOR(S)**
Sarah C. Rutherford, Jun Yin, Levi Pederson, Betsy LaPlant, Maziar Shadman, Hong Li, Michael Leo LeBlanc, Kristie A. Blum, Travis Dockter, Peter Martin, Sin-Ho Jung, Barbara W. Grant, Cara Ann Rosenbaum, Chaitra Shankar Ujjani, Paul M. Barr, Joseph M. Unger, Bruce D. Cheson, Nancy L. Bartlett, Jonathan W. Friedberg, John Paul Leonard

**ABSTRACT / POSTER**
8038 • 371

Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

**SESSION**
Hematologic Malignancies—Plasma Cell Dyscrasia

**AUTHOR(S)**
Shaji Kumar, Simon J. Harrison, Michele Cavo, Javier de La Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kendrick Suzuki, Inho Kim, Francesca Gay, Gabor Mikalo, Elizabeth Punnoose, Wan-Jen Hong, Anjia Sood, Muhammad Jamaluddin, Jeremy A. Ross, James M Pauff, Paulo Cesar Maciag, Philippe Moreau

**ABSTRACT / POSTER**
8509 • 409

Impact of lenalidomide-bortezomib-dexamethasone (Rvd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.

**SESSION**
Hematologic Malignancies—Plasma Cell Dyscrasia

**AUTHOR(S)**

**ABSTRACT / POSTER**
8518 • 418

Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry.

**SESSION**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

**AUTHOR(S)**
Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).

**SESSION**
Hematologic Malignancies—Plasma Cell Dyscrasia

**AUTHOR(S)**

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

**SESSION**
Hematologic Malignancies—Plasma Cell Dyscrasia

**AUTHOR(S)**

Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.

**SESSION**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

**AUTHOR(S)**
Jorge E. Cortes, Elza Lomaia, Anna Turkina, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Christine Rojas, Charles Chuah, Christopher Kevin Arthur, Jane Apperley, Dong-Wook Kim, Andreas Hochhaus, Philippe H. Roussetot, Gianantonio Rosti, Michael J. Mauro, Jeffrey Howard Lipton, Daniel Naranja, Guohui Liu, Shouryadeep Srivastava, Michael W.N. Deininger

Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.

**SESSION**
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**AUTHOR(S)**
Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.

AUTHOR(S)

ABSTRACT
Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.

AUTHOR(S)
David E. Kozono, Elad Sharon, Jennifer Le-Rademacher, Erin Twohy, Tyler J. Zemla, Yujia Wen, Mark Watson, Elie G. Dib, John M. Kirkwood, Gary H. Lyman, Jarushka Naidoo, Andrew B. Nixon, Elizabeth A. Mittendorf

ABSTRACT / POSTER TPS3154 • 218
Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

AUTHOR(S)
Martin Gutierrez, Vivek Subbiah, John J. Nemunaitis, Niharika B. Mettu, Kyriakos P. Papadopoulos, Minal A. Barve, Luis Feliz, Christine Francis Lihou, Chenwei Tian, Tao Ji, Ian M. Silverman, Rashmi Chugh, Mansoor N. Saleh

ABSTRACT / POSTER 3606 • 338
Circulating stromal cells as a potential blood-based biomarker for screening invasive solid tumors.

AUTHOR(S)
Daniel Adams, Steven H. Lin, Harvey I. Pass, Saranya Chumsri, Rena G. Lapidus, Martin Edelman, Raymond C. Bergan, Susan Tsai, Rebecca Aft, Sheeraj Pili, Mark Watson, Amy K. Kim, Kazuaki Chikamatsu, Masanori Hayashi, David M Loeb, Navin R. Pinto, R. Katherine Alpaugh, Cha-Mei Tang, Thai Huu Ho, Jeffrey R Marks

ABSTRACT / POSTER 3535 • 265
Symptoms and Survivorship

Patient-reported distress and healthcare utilization in patients with advanced cancer.

SESSION
Symptoms and Survivorship

AUTHOR(S)
Jordan Danielle Hildenbrand, Heesu Park, David Casarett, Alicia Ellis, Kris Herring, Arif Kamal, Steve Power, Jesse D Troy, Steven Wolf, Yousuf Zafar, Thomas William LeBlanc

ABSTRACT / POSTER 12093 • 381

Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML).

SESSION
Symptoms and Survivorship

AUTHOR(S)

ABSTRACT 12000

Impact of palliative care on end-of-life outcomes in hematologic malignancies.

SESSION
Symptoms and Survivorship

AUTHOR(S)
Ari Pelcovits, Dominic Decke, Dana Guyer, Thomas William LeBlanc, Adam J. Olszewski, Pamela Egan

ABSTRACT / POSTER 12026 • 314
Cancer Prevention, Risk Reduction and Genetics

Genetic counseling referrals after next generation sequencing testing.

SESSION
Cancer Prevention, Risk Reduction, and Genetics

AUTHOR(S)
Rafael Gonzalez, Emma Ryan, Catherine Watson, Gloria Broadwater, Noah D. Kauff, Laura J Havrilesky, Andrew Berchuck, John H. Strickler, Edgardo Castellar, Carolyn S. Menendez, Michelle Green, Kyle C Strickland, Rebecca A. Previs

ABSTRACT / POSTER 1515 • 7

The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board.

SESSION
Cancer Prevention, Risk Reduction, and Genetics

AUTHOR(S)
Catherine Watson, Sarah Tait, Lindsay Soo, Jennifer Kay Plichta, Tian Zhang, Edgardo Castellar, Andrew J. Armstrong, Rebecca A. Previs, John H. Strickler, Michelle Green, Michael Datto, Paul Kelly Marcom, Carolyn S. Menendez

ABSTRACT / POSTER 1516 • 8

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA National Precision Oncology Program.

**SESSION**
Care Delivery and Regulatory Policy (Oral Abstract; 5/29/2020, 8-11 am)

**AUTHOR(S)**
Vishal Vashistha, Jenna Armstrong, David Winski, Meghan Price, Bradley J. Hintze, Pradeep Poonnen, Jane Snowdon, Gretchen Purcell Jackson, Dilhan Weeraratne, David Brotman, Neil L. Spector, Michael J. Kelley

**ABSTRACT**
2005

ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).

**SESSION**
Care Delivery and Regulatory Policy

**AUTHOR(S)**
Matthew T Campbell, Tian Zhang, Lynda Chin, Allison Betof Warner, Mathen Mathew

**ABSTRACT / POSTER**
TPS2089 ●81

Multi-institutional comparative effectiveness of advanced cancer longitudinal imaging response evaluation methods: Current practice versus artificial intelligence-assisted.

**SESSION**
Care Delivery and Regulatory Policy

**AUTHOR(S)**
Andrew Dennis Smith, Brian C. Allen, Asser Abou Elkassem, Rafah Mresh, Seth T. Lirette, Yujan Shrestha, J. David Giese, Reece Stevens, Dillon Williams, Ahmed Farag, Ahmed Khalaf

**ABSTRACT / POSTER**
2010 ● 2

Changes in cancer mortality rates after the adoption of the Affordable Care Act.

**SESSION**
Care Delivery and Regulatory Policy

**AUTHOR(S)**
Anna Lee, Kanan Shah, Junzo P. Chino, Fumiko Chino

**ABSTRACT**
2003

Out-of-pocket cost of screening with breast MRI for women at high risk for breast cancer.

**SESSION**
Care Delivery and Regulatory Policy

**AUTHOR(S)**
I-Wen Pan, Kevin C. Oeffinger, Ya-Chen T. Shih; University of Texas MD Anderson Cancer Center, Houston, TX; Duke University, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX

**ABSTRACT / POSTER**
2017 ● 9
Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: A cost-effectiveness analysis.

AUTHOR(S)
Emma Ryan, Julia Salinaro, Laura J Havrilesky, Brittany Anne Davidson

A randomized controlled trial (RCT) testing a mobile application (app) to identify cancer treatment-related financial assistance.

AUTHOR(S)
Aaron Tamasky, George Nhat Tran, Jonathan Nicolla, Fred Andrew Paul Friedman, Steven Wolf, Jesse D Troy, Anthony Derek Sung, Kanan Shah, Jakob Oury, Jillian C Thompson, Ben Gagosian, Kathryn I. Pollak, Ian Manners, Yousuf Zafar

Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma.

AUTHOR(S)
Pradeep Poonnen, Olivia Dong, David Winski, Shelby D. Reed, Vishal Vashistha, Jill S. Bates, Michael J. Kelley, Deepak Voora

Composite grading algorithm for National Cancer Institute's PRO-CTCAE.

AUTHOR(S)
Amylou C. Dueck, Claus C. Becker, Lauren J. Rogak, Deborah Schrag, Bryce Reeve, Patricia Spears, Mary Lou Smith, Mrinal M. Gounder, Michelle R. Mahoney, Gary K. Schwartz, Antonia Vickery Bennett, Tito R. Mendoza, Charles S. Cleeland, Jeff A. Sloan, Deborah Bruner, Giæla Schwab, Thomas Michael Atkinson, Gita Thanarajasangam, Monica M. Bertagnolli, Ethan M. Basch
Pediatric Oncology

Assisted reproductive technology outcomes in childhood cancer survivors: A report from the Childhood Cancer Survivor Study.

SESSION
Pediatric Oncology

AUTHORS
Kimberly W. Keefe, Andrea Lanes, Kayla Stratton, Daniel M. Green, Eric Jessen Chow, Kevin C. Oeffinger, Sara Barton, Lisa Diller, Yutaka Yasui, Wendy M. Leisenring, Gregory T. Armstrong, Elizabeth S. Ginsburg

ABSTRACT / POSTER 10528 ● 415

Neuromuscular dysfunction and associated health/socioeconomic outcomes: A report from the Childhood Cancer Survivor Study (CCSS).

SESSION
Pediatric Oncology

AUTHORS

ABSTRACT / POSTER 10546 ● 433

Underdiagnosis and undertreatment of modifiable cardiovascular risk factors: A Childhood Cancer Survivor Study (CCSS) report.

SESSION
Pediatric Oncology II

AUTHORS
Eric Jessen Chow, Yan Chen, Gregory T. Armstrong, Laura-Mae Baldwin, Todd M. Gibson, Melissa M. Hudson, Aaron McDonald, Paul C. Nathan, Karen L Syrjala, Emily S. Tonozeros, Kevin C. Oeffinger, Yutaka Yasui

ABSTRACT 10515

Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients ≥18 months with unfavorable histology and without MYCN amplification: A Children’s Oncology Group (COG) report.

SESSION
Pediatric Oncology I

AUTHORS
Navin R. Pinto, Arlene Naranjo, Emily Hibbitts, Xiangming Ding, Rachelle Tibbetts, Rebekah Kennedy, Ruthann Pfau, Michael D. Hogarty, Susan G. Kreisman, Meredith Irwin, Julie R. Park, Shahab Asgharzadeh

ABSTRACT 10502

HAGHL genetic variants increase first fracture risk (FFR) in female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort Study (SJLIFE).

SESSION
Pediatric Oncology

AUTHORS
Cindy Im, Nan Li, Wonjong Moon, Lindsay M. Morton, Wendy M. Leisenring, Rebecca M. Howell, Kevin C. Oeffinger, Charles A. Sklar, Carmen Louise Wilson, Yadav Sapkota, Kirsten K. Ness, Melissa M. Hudson, Leslie L. Robison, Smita Bhatia, Gregory T. Armstrong, Yutaka Yasui

ABSTRACT / POSTER 10554 ● 441

Treatment intensity and risk of chronic health conditions and late mortality among long-term survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study.

SESSION
Pediatric Oncology

AUTHORS

ABSTRACT / POSTER 10553 ● 440


SESSION
Pediatric Oncology

AUTHORS

ABSTRACT / POSTER 10550 ● 437

AUTHOR(S)
Neal E. Ready, Apama Raj Parikh, Patrice Lazure, Morgan Peniuta, Marianne Davies, Monica Augustyniak, Jeffrey Caterino, Robert Lewandowski, Alexander J. Lazar, Suzanne Murray

ABSTRACT / POSTER 11028 • 285